Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The total serum 1,25(OH)2D in the doxercalciferol group increased from 100.79 to 148 at 12 months and 148.4 at 24 months compared with a decrease in the placebo group from 114 to 113.7 at 12 months and 99.4 at 24 months.

Source: Vitamin D metabolites. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In a 1-year pilot randomized double-blind, placebo-controlled study, 55 postmenopausal women (aged 60 to 71 years) with osteopenia were treated for a year with either doxercalciferol or placebo, and 41 women completed an optional second year.

Source: Abstract.

Participants were screened to confirm normal baseline serum and urinary biochemical parameters.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Efficacy and safety of doxercalciferol (1α hydroxyvitamin D2) on spine and femur bone mineral density in postmenopausal osteopenic women

Study design awaiting verification · Frontiers in Endocrinology · 2026

Original publication title

Efficacy and safety of doxercalciferol (1α hydroxyvitamin D2) on spine and femur bone mineral density in postmenopausal osteopenic women

J. C. Gallagher; Richard Mazess

Copyright © 2026 Gallagher and Mazess.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The results show that doxercalciferol treatment showed no difference from the placebo group on bone loss at 12 months; however, at 24 months, doxercalciferol showed significant prevention of bone loss from the femoral neck and spine.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

The use of small doses of vitamin D3 analogs or metabolites is common in the prevention of renal osteodystrophy. Their use in the treatment of osteoporosis has been limited by their potent adverse effects, causing hypercalcemia and hypercalciuria. We evaluated a vitamin D2 analog, i.e., 1α-hydroxyvitamin D2 (doxercalciferol), that has a lower incidence of adverse effects.

Source: Background

Abstract: What methods does the paper describe?

In a 1-year pilot randomized double-blind, placebo-controlled study, 55 postmenopausal women (aged 60 to 71 years) with osteopenia were treated for a year with either doxercalciferol or placebo, and 41 women completed an optional second year. The dose of 1 µg was increased by 1 µg at weekly intervals to a maximum of 5 µg. The daily dose of doxercalciferol averaged 4.1 µg after 12 months and 3.6 µg after 24 months. Bone mineral density (BMD) measurements by dual-energy X-ray absorptiometry (DEXA) of the spine and femoral neck were obtained at 6-month intervals for 24 months.

The serum and urine calcium levels were measured frequently for safety.

Source: Methods

Abstract: Results

In the primary intention-to-treat (ITT) analysis at 12 months, there was no significant difference between the two groups for femoral neck and spine BMD. At 24 months, there was a significant difference in favor of doxercalciferol for femoral neck BMD, with the treatment/placebo difference being 1.70% (p < 0.047); for spine BMD, the treatment/placebo difference was 1.1% (p = 0.36). In the per-protocol analysis at 12 months, the doxercalciferol/placebo difference for femoral neck was 0.5% (p = 0.497) and for spine BMD was 1.6% (p = 0.071).

At 24 months, the doxercalciferol/placebo difference for femoral neck BMD was 2.2% (p < 0.017) and for spine BMD was 2.4% (p < 0.041). Over 24 months, there were five mild hypercalcemia events, 2.54 mmol/L (>10.2 mg/dl), in five patients. The mean 24-h urine calcium increased by 3.75 mmol (150 mg), with 16 episodes of hypercalciuria, 10 mmol (>400 mg), in 12 patients.

Source: Results

Abstract: Conclusions

The results show that doxercalciferol treatment showed no difference from the placebo group on bone loss at 12 months; however, at 24 months, doxercalciferol showed significant prevention of bone loss from the femoral neck and spine.

Source: Conclusions
Authors’ abstract

Background

The use of small doses of vitamin D3 analogs or metabolites is common in the prevention of renal osteodystrophy. Their use in the treatment of osteoporosis has been limited by their potent adverse effects, causing hypercalcemia and hypercalciuria. We evaluated a vitamin D2 analog, i.e., 1α-hydroxyvitamin D2 (doxercalciferol), that has a lower incidence of adverse effects.

Methods

In a 1-year pilot randomized double-blind, placebo-controlled study, 55 postmenopausal women (aged 60 to 71 years) with osteopenia were treated for a year with either doxercalciferol or placebo, and 41 women completed an optional second year. The dose of 1 µg was increased by 1 µg at weekly intervals to a maximum of 5 µg. The daily dose of doxercalciferol averaged 4.1 µg after 12 months and 3.6 µg after 24 months. Bone mineral density (BMD) measurements by dual-energy X-ray absorptiometry (DEXA) of the spine and femoral neck were obtained at 6-month intervals for 24 months.

The serum and urine calcium levels were measured frequently for safety.

Results

In the primary intention-to-treat (ITT) analysis at 12 months, there was no significant difference between the two groups for femoral neck and spine BMD. At 24 months, there was a significant difference in favor of doxercalciferol for femoral neck BMD, with the treatment/placebo difference being 1.70% (p < 0.047); for spine BMD, the treatment/placebo difference was 1.1% (p = 0.36). In the per-protocol analysis at 12 months, the doxercalciferol/placebo difference for femoral neck was 0.5% (p = 0.497) and for spine BMD was 1.6% (p = 0.071).

At 24 months, the doxercalciferol/placebo difference for femoral neck BMD was 2.2% (p < 0.017) and for spine BMD was 2.4% (p < 0.041). Over 24 months, there were five mild hypercalcemia events, 2.54 mmol/L (>10.2 mg/dl), in five patients. The mean 24-h urine calcium increased by 3.75 mmol (150 mg), with 16 episodes of hypercalciuria, 10 mmol (>400 mg), in 12 patients.

Conclusions

The results show that doxercalciferol treatment showed no difference from the placebo group on bone loss at 12 months; however, at 24 months, doxercalciferol showed significant prevention of bone loss from the femoral neck and spine.

Clinical Trial Registration

https://clinicaltrials.gov/, identifier NCT07660536.

Publication and source details

Original title: Efficacy and safety of doxercalciferol (1α hydroxyvitamin D2) on spine and femur bone mineral density in postmenopausal osteopenic women

J. C. Gallagher; Richard Mazess

Frontiers in Endocrinology · 2026

* Correspondence: J. C. Gallagher, jcg@creighton.eduCopyright © 2026 Gallagher and Mazess.2026Gallagher and Mazesshttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. The author(s) declared that this work received funding from Bone Care International. Grant support for the study was provided by Bone Care International. Bone Care was involved in both the study design in conjunction with the senior author (JCG) and collection of the data. Analysis of the data was performed by an independent statistician (Barry Storer PhD at the Fred Hutchinson Cancer Center). Bone Care was not involved in the decision to publish the results in this journal, a decision that was made by the senior author (JCG) and had no role in the writing of the paper.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:03:40.430848+00:00

DOI: 10.3389/fendo.2026.1640045 · PMC13445195